359 related articles for article (PubMed ID: 21422814)
1. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations.
Banzhoff A; Haertel S; Praus M
Hum Vaccin; 2011 May; 7(5):539-48. PubMed ID: 21422814
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
[TBL] [Abstract][Full Text] [Related]
4. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus.
Zuccotti GV; Pariani E; Scaramuzza A; Santoro L; Giani E; Macedoni M; Gazzarri A; Anselmi G; Amendola A; Zanetti A
Diabet Med; 2011 Dec; 28(12):1530-6. PubMed ID: 21916971
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
[TBL] [Abstract][Full Text] [Related]
6. In vitro assessment of the allergenicity of novel MF59-adjuvanted pandemic H1N1 influenza vaccine produced in dog kidney cells.
Bencharitiwong R; Leonard S; Tsai T; Nowak-Węgrzyn A
Hum Vaccin Immunother; 2012 Jul; 8(7):863-5. PubMed ID: 22777093
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine.
Rouleau I; De Serres G; Drolet JP; Skowronski DM; Ouakki M; Toth E; Landry M; Ménard S; Gagnon R
Vaccine; 2013 Dec; 31(50):5989-96. PubMed ID: 24144473
[TBL] [Abstract][Full Text] [Related]
8. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.
Esposito S; Pugni L; Daleno C; Ronchi A; Valzano A; Serra D; Mosca F; Principi N
Pediatrics; 2011 May; 127(5):e1161-8. PubMed ID: 21464195
[TBL] [Abstract][Full Text] [Related]
9. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M
Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
Knuf M; Leroux-Roels G; Rümke H; Rivera L; Pedotti P; Arora AK; Lattanzi M; Kieninger D; Cioppa GD
Hum Vaccin Immunother; 2015; 11(2):358-76. PubMed ID: 25621884
[TBL] [Abstract][Full Text] [Related]
11. An early (3-6 weeks) active surveillance study to assess the safety of pandemic influenza vaccine Focetria in a province of Emilia-Romagna region, Italy - part one.
Candela S; Pergolizzi S; Ragni P; Cavuto S; Nobilio L; Di Mario S; Dragosevic V; Groth N; Magrini N;
Vaccine; 2013 Feb; 31(10):1431-7. PubMed ID: 22766247
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults.
Herbinger KH; von Sonnenburg F; Nothdurft HD; Perona P; Borkowski A; Fragapane E; Nicolay U; Clemens R
Hum Vaccin Immunother; 2014; 10(1):92-9. PubMed ID: 24047817
[TBL] [Abstract][Full Text] [Related]
13. A population based cohort study to assess the safety of pandemic influenza vaccine Focetria in Emilia-Romagna region, Italy - part two.
Moro ML; Nobilio L; Voci C; Di Mario S; Candela S; Magrini N;
Vaccine; 2013 Feb; 31(10):1438-46. PubMed ID: 22885015
[TBL] [Abstract][Full Text] [Related]
14. Incidence of narcolepsy before and after MF59-adjuvanted influenza A(H1N1)pdm09 vaccination in South Korean soldiers.
Kim WJ; Lee SD; Lee E; Namkoong K; Choe KW; Song JY; Cheong HJ; Jeong HW; Heo JY
Vaccine; 2015 Sep; 33(38):4868-72. PubMed ID: 26238720
[TBL] [Abstract][Full Text] [Related]
15. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.
Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli C; Groth N; Levin Y; Del Giudice G
Hum Vaccin Immunother; 2014; 10(6):1701-10. PubMed ID: 24732325
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the adverse events associated with MF59-adjuvanted and non-adjuvanted H1N1 vaccines in healthy young male Korean soldiers.
Hwang SM; Kim HL; Min KW; Kim M; Lim JS; Choi JM; Chun BC; Kim MJ; Lee SM; Kim SY; Jeon HH
Jpn J Infect Dis; 2012; 65(3):193-7. PubMed ID: 22627298
[TBL] [Abstract][Full Text] [Related]
17. A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic.
Reynales H; Astudillo P; de Vallière S; Hatz C; Schlagenhauf P; Rath B; Velentgas P; Fariña A; Sales-Carmona V; Groth N
Vaccine; 2012 Oct; 30(45):6436-43. PubMed ID: 22902681
[TBL] [Abstract][Full Text] [Related]
18. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects.
Gasparini R; Schioppa F; Lattanzi M; Barone M; Casula D; Pellegrini M; Veitch K; Gaitatzis N
Int J Clin Pract; 2010 Mar; 64(4):432-8. PubMed ID: 20039974
[TBL] [Abstract][Full Text] [Related]
19. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
[TBL] [Abstract][Full Text] [Related]
20. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.
Black S; Della Cioppa G; Malfroot A; Nacci P; Nicolay U; Pellegrini M; Sokal E; Vertruyen A
Vaccine; 2010 Oct; 28(45):7331-6. PubMed ID: 20813217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
